Authors
Latest:
Considerations for choosing an AI scribe toolAI scribe solutions are one of the easiest technologies to deploy into existing workflows, writes Vadim Khazan.
Latest:
Key Takeaways on the Evolving NMIBC Treatment LandscapeThe panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
Latest:
EP. 1B: Advanced/Metastatic Prostate Cancer: Disease Overview, Treatment Strategies, and Unmet NeedsIn this companion article, Judd W. Moul, MD, of Duke University Medical Center, shares expert insights into factors affecting treatment decisions in metastatic hormone-sensitive and castration-resistant prostate cancer.
Latest:
Male sexual health and reproductive medicine: All that glitters is not gold"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.
Latest:
Yahir A. Santiago-Lastra, MD, discusses barriers to vaginal estrogen access"The black box warning affects that ability for them to get access to that critical drug, vaginal estrogen," says Yahir A. Santiago-Lastra, MD.
Latest:
Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPC"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.
Latest:
Patient selection for cytoreductive nephrectomy in 2025"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
Latest:
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD.
Latest:
Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR AlterationPanelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.
Latest:
Integrating ctDNA in NMIBC: Promise and practical challengesFrom a practical standpoint, integrating ctDNA into clinical practice poses challenges.
Latest:
Understanding molecular phenotypes in RCC may help drive treatment decisionsBenjamin L. Maughan, MD, PharmD, highlights key studies presented at the 2024 ASCO Annual Meeting regarding biomarkers and the evolution of first-line treatments in renal cell carcinoma.
Latest:
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC“Widespread adoption of the BCG plus mitomycin regimen would actually help to resolve that BCG shortage," says Professor Dickon Hayne.
Latest:
GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical TrialFor the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.
Latest:
Expert compares Aquablation with TURP for treatment of BPH"The main benefit, I guess, for Aquablation over TURP, is the fact that the sexual side effects are much better when compared to TURP," says Mohamad Baker Berjaoui, MD.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Unmet Needs and Clinical Challenges for PSMA ImagingOliver Sartor, MD, discusses how unmet needs and clinical challenges for PSMA imaging in prostate cancer patients include standardizing interpretation criteria, addressing false negatives in certain tumor phenotypes, improving accessibility and cost-effectiveness, and developing strategies for patients with low PSMA expression or PSMA-negative disease.
Latest:
Upper tract urothelial carcinoma: An in-depth review for urologists"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.
Latest:
Hybrid approach to telehealth effective in rural communities“A hybrid telehealth approach expands access to specialized care, reduces travel burdens, promotes timely interventions, and enables continuous management of health conditions,” writes Kara Hartl, MD.
Latest:
Unmet Needs and Treatment Gaps in Prostate CancerThe panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
Latest:
ADT Treatment Considerations and Unmet Needs in Prostate CancerExperts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.
Latest:
Experts discuss expanding use of vibegron for OABGrace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Episode 3 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric ChallengesWayne Kuang, MD; and Matt T. Rosenberg, MD, discuss how overactive bladder presents with distinct pathophysiological mechanisms between genders, requires different diagnostic approaches when distinguishing from benign prostatic hyperplasia in men, impacts quality of life in older adults, benefits from early primary care intervention, and necessitates improved patient advocacy and educational initiatives for optimal management outcomes.
Latest:
Expert examines tech-driven burnout in healthcare“Health care technology has largely failed to deliver on its promise to make the management of patient care simpler, easier, and less stressful for clinicians,” writes Oron Afek.
Latest:
What role can automation play in solving the prior authorization issue?If automation can enhance efficiency and reduce provider dissatisfaction while improving patient health, there’s a strong case for introducing automation into the mix, writes industry expert Eric Demers.
Latest:
Tax deduction can offset your practice’s cost for new equipment and technologySection 179 of the IRS Tax Code allows businesses to deduct up to the full purchase price of qualified equipment, technology, software, and other qualifying purchases from their taxes within the same tax year.
Latest:
Expert explains the crucial role of interoperability in medical billing"Without interoperability, electronic insurance billing would be nearly impossible. Insurance payers, healthcare providers and claim clearinghouses all rely on interoperability at their core," writes Lisa Taylor.
Latest:
Katherine Chan, MD, outlines the design of the pivotal LEGEND trialKatherine Chan, MD, MPH, details the design of the pivotal phase 1/2 LEGEND trial, assessing the safety and efficacy of detalimogene voraplasmid in NMIBC.
Latest:
Dean Laganosky, M.D., named Urology Trailblazer for 2024This prestigious recognition is given to one urologist or administrator each year who has significantly contributed to the field of urology within the first ten years of their practice.
